Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 24 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)CompletedNCT04199104Phase 3Results posted
• Acalabrutinib for the Treatment of Chronic Graft Versus Host DiseaseActive, not recruitingNCT04198922Phase 2Results posted
• Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedNCT04197986Phase 3Results posted
• Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR StudyActive, not recruitingNCT04197713Phase 1Results posted
• Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
• Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT04195698Phase 3Results posted
• A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerActive, not recruitingNCT04194944Phase 3Results posted
• A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular CarcinomaCompletedNCT04194801Phase 1/2Results posted
• Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
• Futibatinib in Patients With Specific FGFR AberrationsTerminatedNCT04189445Phase 2Results posted
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCompletedNCT04186871Phase 2Results posted
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)CompletedNCT04173494Phase 3Results posted
• A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)CompletedNCT04172675Phase 2Results posted
• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedNCT04172597Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial SpondyloarthritisCompletedNCT04169373Phase 3Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaCompletedNCT04167462Phase 3Results posted
• Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaCompletedNCT04164979Phase 2Results posted
• A Phase II Study in Adult Patients With Moderate to Severe Atopic DermatitisCompletedNCT04162899Phase 2Results posted
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTerminatedNCT04161391Phase 1/2Results posted
• ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate CancerTerminatedNCT04159896Phase 2Results posted
• A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory OsteosarcomaCompletedNCT04154189Phase 2Results posted
• Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%TerminatedNCT04139317Phase 2Results posted
• A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788CompletedNCT04132050Phase 3Results posted
• PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyCompletedNCT04129931Phase 2Results posted
• Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)CompletedNCT04126733Phase 2Results posted
• Sitravatinib in Metastatic Breast CancerTerminatedNCT04123704Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)TerminatedNCT04119453Phase 2Results posted
• Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal CancerActive, not recruitingNCT04117945Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD TherapyTerminatedNCT04115839Phase 3Results posted
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD TherapyTerminatedNCT04115748Phase 3Results posted
• Dasatinib In Waldenström MacroglobulinemiaTerminatedNCT04115059Phase 1Results posted
• An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSUCompletedNCT04109313Phase 2Results posted
• Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)CompletedNCT04105010Phase 1/2Results posted
• Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR AlterationsActive, not recruitingNCT04096417Phase 2Results posted
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene RearrangementsTerminatedNCT04093362Phase 3Results posted
• A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)CompletedNCT04093024Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaCompletedNCT04092452Phase 2Results posted
• Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive UveitisActive, not recruitingNCT04088409Phase 3Results posted
• Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic CholangiocarcinomaTerminatedNCT04088188Phase 1Results posted
• A Study of Baricitinib in Participants With Rheumatoid ArthritisCompletedNCT04086745Phase 4Results posted
• A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein OcclusionCompletedNCT04085341Phase 2Results posted
• A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene AlterationsCompletedNCT04083976Phase 2Results posted
• Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor IxazomibTerminatedNCT04079738Phase 1/2Results posted
• Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
• A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04075396Phase 1/2Results posted
• Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT04075292Phase 3Results posted
• Study of Safety and Proof of the Mechanism of BLZ945 in ALS PatientsTerminatedNCT04066244Phase 2Results posted
• Senolytic Therapy to Modulate Progression of Alzheimer's DiseaseCompletedNCT04063124Phase 1/2Results posted
• A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)CompletedNCT04062448Phase 2Results posted
• A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the BloodCompletedNCT04060719Phase 1Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)CompletedNCT04057573Phase 3Results posted
• A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.CompletedNCT04057118Phase 2Results posted
• A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic FunctionCompletedNCT04056468Phase 1Results posted
• A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy KidneysCompletedNCT04056455Phase 1Results posted
• Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)CompletedNCT04056195Phase 2Results posted
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
• Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)CompletedNCT04052425Phase 3Results posted
• Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT04051827Phase 1Results posted
• Derazantinib and Atezolizumab in Patients With Urothelial CancerCompletedNCT04045613Phase 1/2Results posted
• A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)CompletedNCT04042376Phase 4Results posted
• A Renal Impairment Study for PF-06651600TerminatedNCT04037865Phase 1Results posted
• A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's SyndromeTerminatedNCT04035668Phase 2Results posted
• Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid TumorsCompletedNCT04034238Phase 1Results posted
• Study of Evobrutinib in Participants With RMSTerminatedNCT04032171Phase 3Results posted
• Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)TerminatedNCT04032158Phase 3Results posted
• A Study of TAS-120 in Patients With Metastatic Breast CancerTerminatedNCT04024436Phase 2Results posted
• Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney CancerActive, not recruitingNCT04022343Phase 2Results posted
• Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedNCT04016805Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy VolunteersCompletedNCT04016077Phase 1Results posted
• Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung CancerCompletedNCT04012619Phase 1Results posted
• Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsCompletedNCT04008706Phase 3Results posted
• Long-Term PF-06651600 for the Treatment of Alopecia AreataCompletedNCT04006457Phase 3Results posted
• Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)TerminatedNCT04003623Phase 2Results posted
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)TerminatedNCT04003610Phase 2Results posted
• Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy BodiesCompletedNCT04002674Phase 2Results posted
• Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate CancerTerminatedNCT03999515Phase 2Results posted
• Imatinib for Pain in Sickle Cell AnemiaTerminatedNCT03997903Phase 1/2Results posted
• Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisCompletedNCT03996291Phase 2Results posted
• Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic CarcinomaCompletedNCT03990571Phase 2Results posted
• Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationTerminatedNCT03978637Phase 1/2Results posted
• A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)CompletedNCT03978520Phase 2Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)CompletedNCT03976375Phase 3Results posted
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerActive, not recruitingNCT03975647Phase 3Results posted
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingNCT03974022Phase 1/2Results posted
• Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild AsthmaCompletedNCT03971539Phase 1Results posted
• Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its MetaboliteCompletedNCT03968848Phase 1Results posted
• Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate CancerTerminatedNCT03964337Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic ArthritisCompletedNCT03963401Phase 2Results posted
• A Performance and Bioavailability Study of Entrectinib in Healthy Volunteers.CompletedNCT03961100Phase 1Results posted
• Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.TerminatedNCT03958955Phase 2Results posted
• Cabozantinib and Pembrolizumab for Advanced Metastatic MelanomaTerminatedNCT03957551Phase 1/2Results posted
• Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host DiseaseActive, not recruitingNCT03954236Phase 2Results posted
• A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMDCompletedNCT03953079Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic DermatitisCompletedNCT03952559Phase 3Results posted
• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedNCT03952039Phase 3Results posted
• Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsCompletedNCT03945773Phase 2Results posted
• Study of Efficacy and Safety of LOU064 in Inadequately Controlled Asthma PatientsTerminatedNCT03944707Phase 2Results posted
• An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus NephritisTerminatedNCT03943147Phase 2Results posted
• A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Phase 1/2Results posted

← Tyrosine Kinase Inhibitors overview